Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
Date:5/9/2011

lly offset by the use of cash to fund our clinical-stage programs, personnel costs and for other general corporate purposes.  The decrease in receivables in this period was due to the receipt of the $15.0 million milestone payment from Bayer.

Revenues totaled $1.8 million and $3.3 million for the three months ended March 31, 2011 and 2010, respectively.  The revenue earned in 2010 and 2011 resulted primarily from the recognition of a portion of the $35.0 million upfront, non-refundable license fee and reimbursement of third-party development costs under our global license agreement with Bayer.  The decrease in revenues for the three months ended March 31, 2011 was due primarily to an extension of the period over which we recognize the upfront license fee due to an increase in the estimated time over which we expect to complete our obligations under the Bayer license agreement.

For the three months ended March 31, 2011, total operating expenses increased to $17.0 million from $13.2 million for the same period in 2010.  Total operating expenses for the three months ended March 31, 2011 included non-cash, stock-based compensation charges of $2.4 million, or $0.09 per share, compared to charges of $1.6 million, or $0.09 per share, for the same period in 2010.  The increase in total operating expenses between the first quarter of 2010 and 2011 was primarily a result of an increase in research and development expense due mainly to the continued development and progression of our clinical and preclinical programs and the increase in non-cash stock-based compensation expense noted above.  Also contributing was an increase in general and administrative expense due mainly to increases in stock-based compensation expense, consulting and professional outside services and personnel and related costs.

Net loss for the three months ended March 31, 2011 was $15.2 million, or $0.59 per share, compared to a net loss for the
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
3. Ardea Biosciences Prices Public Offering of Common Stock
4. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
10. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
11. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. ... (eslicarbazepine acetate) for use as a once-daily adjunctive ... with epilepsy who are not satisfactorily controlled with conventional ... in patients under 18 years of age. ... disorders and according to Epilepsy Canada, it affects 0.6% ...
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... Fuel Cell Technology On The Ground in Los Angeles and planned for New ... ... ... Virgin Atlantic, one of,the world,s leading long-haul airlines, and General Motors, the world,s,largest automaker, ...
... Company,s Leading microRNA Intellectual ... Property Position ... Allowed Patents, and More Than 60 Pending Patent ... Rosetta Genomics, Ltd. (NASDQ: ROSG) announced,today that the U.S. Patent and ...
... Anatomic Pathology LIS Interface to Digital Pathology Information ... ... March 3 IMPAC Medical,Systems, Inc. (IMPAC), an Elekta company ... laboratories,and Aperio Technologies, (Aperio) a global leader in digital pathology ...
Cached Biology Technology:Virgin Atlantic to Offer Zero-Emissions GM Hydrogen Fuel Cell Limousines to Upper Class Passengers 2Virgin Atlantic to Offer Zero-Emissions GM Hydrogen Fuel Cell Limousines to Upper Class Passengers 3Rosetta Genomics Announces Allowance of Two Additional microRNA Patents 2Rosetta Genomics Announces Allowance of Two Additional microRNA Patents 3Rosetta Genomics Announces Allowance of Two Additional microRNA Patents 4IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology 2IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology 3
(Date:7/11/2014)... Standards and Technology (NIST) need a special tool ... prove that necessity is truly the mother of ... Lorna De Leoz and Stephen Stein, NIST chemists ... is the study of the abundant, often-branched sugar ... and lipids and influence cellular processes, including immunity, ...
(Date:7/11/2014)... An international team of researchers, including scientists from the ... just a reported a major step in understanding photosynthesis, ... now maintains the oxygen in its atmosphere and which ... on earth. , The researchers report the first ... reaction, namely the step in which a specific protein ...
(Date:7/11/2014)... transplantation of mesenchymal stem cells can stimulate neurogenesis in ... Alzheimer,s disease (AD) and improve tissue and function injury ... reported on the therapeutic effect of adipose-derived stem cells ... effect on oxidative injury and neurogenesis in the brain ... School of Life Sciences, Tsinghua University, China transplanted ADSCs ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... To most people in the southwestern U.S., the April 4 ... But on a group of inch-long fish that exist nowhere ... the ground in Nevada,s Mojave Desert, it unleashed a veritable ... the event on cameras installed above and below the water,s ...
... (EPA) has awarded nearly $2.5 million to 11 ... environmental areas: monitoring and control of air emissions, ... monitoring, water infrastructure, homeland security, nanotechnology and innovation ... of concept" awards from EPA, and will use ...
... JOLLA, Calif., May 11, 2010 -- Investigators from around ... on Friday, May 7, to share their knowledge of ... non-coding nucleic acids turn off proteins and have been ... numerous other conditions. "The discovery that small ...
Cached Biology News:'Tsunami' video sheds light on struggling pupfish 2'Tsunami' video sheds light on struggling pupfish 3'Tsunami' video sheds light on struggling pupfish 4'Tsunami' video sheds light on struggling pupfish 5EPA awards small businesses to develop new environmental technologies 2Researchers share insights into RNA 2
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Bovine Serum Albumin Peroxidase Stabilizer Solution, 1 L...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
...
Biology Products: